Skeletal Mechanosensing Failure in Bone Disorders: Mechanisms, Clinical Implications, and Emerging Therapies

Abstract

Skeletal mechanosensing refers to the bone tissue’s ability to perceive and respond to mechanical stimuli, a process essential for maintaining bone mass and structural integrity. Failure of this system is increasingly recognized as a critical factor underlying diverse bone disorders, including osteoporosis, osteogenesis imperfecta, and skeletal fragility syndromes. Recent research highlights how defects in mechanotransduction pathways compromise bone health, influence disease progression, and affect therapeutic outcomes. This review synthesizes current evidence on the epidemiology, mechanisms, clinical presentation, diagnostic approaches, and emerging therapies for skeletal mechanosensing failure, providing actionable insights for healthcare professionals managing bone disorders.

Introduction

Bones are dynamic tissues that constantly remodel in response to mechanical forces. Mechanosensing, the cellular process of detecting and translating physical stimuli into biochemical signals, is fundamental to skeletal adaptation and homeostasis. Disruption in this capability termed mechanosensing failure contributes to the pathogenesis of various bone disorders, affecting both pediatric and adult populations. With the rising prevalence of osteoporosis and fractures globally, understanding the role of mechanosensing in bone physiology and pathology has significant clinical implications. This review delves into the molecular and cellular basis of skeletal mechanosensing, its failure in disease states, and the evolving landscape of diagnostic and therapeutic strategies.

Epidemiology / Disease Burden

Skeletal mechanosensing failure is implicated in the pathophysiology of common and rare bone disorders. Osteoporosis, affecting over 200 million people worldwide, prominently features impaired mechanotransduction, contributing to reduced bone strength and increased fracture risk. Similarly, conditions like disuse osteopenia, microgravity-induced bone loss in astronauts, and genetic disorders such as osteogenesis imperfecta manifest with compromised skeletal mechanosensitivity. The burden of these conditions is reflected in increased morbidity, healthcare costs, and reduced quality of life, emphasizing the need for improved recognition and targeted interventions.

Pathophysiology

Mechanosensing in bone is primarily mediated by osteocytes, which reside within the mineralized matrix and form an extensive network through their dendritic processes. Mechanical loading generates fluid flow within the lacuno-canalicular system, activating mechanosensitive ion channels, integrins, and the cytoskeleton. These signals propagate through pathways involving focal adhesion kinase, Wnt/β-catenin, and prostaglandin E2, ultimately regulating bone formation and resorption. Failure of mechanosensing can result from genetic mutations (e.g., in LRP5, SOST/sclerostin, or PIEZO1/2), age-related cellular senescence, chronic inflammation, or altered physical activity. These defects lead to imbalances in bone remodeling, impaired adaptation to mechanical demands, and increased susceptibility to microdamage and fractures.

Risk Factors

Numerous factors predispose individuals to mechanosensing failure. Aging is a principal risk, associated with decreased osteocyte viability and responsiveness. Genetic mutations affecting mechanotransduction components, immobilization (e.g., prolonged bed rest), and microgravity exposure are established contributors. Comorbidities such as diabetes, glucocorticoid excess, chronic kidney disease, and inflammatory arthritis exacerbate mechanosensory dysfunction. Lifestyle factors, including inadequate physical activity and poor nutrition (notably calcium and vitamin D deficiency), further compromise bone mechanoadaptation.

Clinical Features

Patients with skeletal mechanosensing failure may present with low-trauma fractures, progressive bone loss, delayed fracture healing, and skeletal deformities. Clinical manifestations vary depending on the underlying etiology: osteoporosis and disuse osteopenia often remain silent until a fracture occurs, whereas genetic syndromes may present in childhood with recurrent fractures, bone pain, and growth abnormalities. Subtle signs such as muscle weakness and reduced mobility may also reflect underlying bone mechanosensitivity impairment.

Diagnosis

Diagnosis of mechanosensing failure relies on a combination of clinical assessment, imaging, and laboratory evaluation. Dual-energy X-ray absorptiometry (DXA) remains the gold standard for assessing bone mineral density, but does not directly measure mechanosensitivity. High-resolution peripheral quantitative computed tomography (HR-pQCT) and finite element analysis provide insights into bone microarchitecture and strength. Biomarkers such as sclerostin and bone turnover markers can suggest impaired mechanotransduction. Genetic testing may be indicated in suspected monogenic disorders. Functional assessments, including response to mechanical loading, are primarily research tools but may gain clinical relevance as technology advances.

Treatment & Management

Current management strategies focus on optimizing bone mass, reducing fracture risk, and addressing reversible risk factors. Weight-bearing exercise remains a cornerstone, stimulating bone formation through mechanical loading. Pharmacological interventions include bisphosphonates, denosumab, parathyroid hormone analogs, and sclerostin inhibitors, each targeting distinct aspects of bone remodeling. Correction of nutritional deficiencies and management of comorbidities are essential adjuncts. In rare genetic disorders, tailored therapies such as growth hormone or gene editing are under investigation. Multidisciplinary care, involving endocrinologists, orthopedic surgeons, physiotherapists, and geneticists, enhances patient outcomes.

Recent Advances / Emerging Therapies

Ongoing research is expanding therapeutic options for mechanosensing failure. Anabolic agents targeting the Wnt/β-catenin pathway, such as romosozumab (a sclerostin antibody), have demonstrated significant improvements in bone density and strength. Small molecule activators of mechanosensitive channels (e.g., PIEZO1 agonists) are in preclinical development. Advances in tissue engineering and 3D bioprinting aim to restore functional bone in severe cases. Wearable devices and rehabilitation robotics offer novel approaches to enhance mechanical stimulation in immobilized or osteoporotic patients. These innovations hold promise for addressing unmet clinical needs in bone fragility syndromes.

Guideline Recommendations

International guidelines emphasize a multifaceted approach to bone health, integrating lifestyle modification, pharmacotherapy, and risk factor management. The International Osteoporosis Foundation and American Society for Bone and Mineral Research advocate for routine assessment of fracture risk, judicious use of antiresorptive and anabolic agents, and promotion of regular physical activity. For secondary bone disorders, treatment of underlying conditions and avoidance of immobilization are key. Genetic counseling is recommended for heritable syndromes. Ongoing guideline updates increasingly recognize the importance of mechanosensing in disease pathogenesis and therapeutic response.

Conclusion

Skeletal mechanosensing failure is a pivotal driver of bone fragility, underpinning a spectrum of disorders from osteoporosis to rare genetic diseases. Advances in the understanding of mechanotransduction pathways have informed novel diagnostic and therapeutic approaches, with significant implications for clinical practice. Early identification and intervention, guided by emerging evidence and consensus recommendations, can mitigate disease progression and improve patient outcomes. As research continues to elucidate the molecular mechanisms of mechanosensing, personalized and mechanism-based therapies are likely to transform the management of bone disorders in the years ahead.